Lv6
1650 积分 2025-04-08 加入
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain
3天前
已完结
FDA CDER analysis of non-human primate (NHP) data in monoclonal antibody (mAb) development to support the streamlining of nonclinical safety studies
6天前
已完结
Initial activation of cyclin‐B1–cdc2 kinase requires phosphorylation of cyclin B1
2个月前
已关闭
FIH dose selection beyond MABEL: Optimizing phase 1 clinical trial starting dose whilst protecting patient safety
4个月前
已完结
Fatal tumor lysis syndrome in a pediatric patient with acute lymphoblastic leukemia treated with venetoclax
5个月前
已完结
Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
8个月前
已完结
Practical Considerations in Determining Adversity and the No-Observed-Adverse-Effect-Level (NOAEL) in Nonclinical Safety Studies: Challenges, Perspectives and Case Studies
8个月前
已完结
Points to consider regarding the use and implementation of virtual controls in nonclinical general toxicology studies
8个月前
已完结
Replacing concurrent controls with virtual control groups in rat toxicity studies
8个月前
已完结
皖公网安备34019202002308
